Sanofi warns dengue vaccine less safe than previously thought

30 November 2017

French drugmaker Sanofi (Euronext: SAN) says it expects to take a post-tax hit of about 100 million euros ($118 million) after new safety data showed its dengue vaccine Dengvaxia could be harmful to those not previously infected with the disease.

As a result, the company says it will request authorities slim down its label to ensure that vaccination is not recommended for those who have not been infected in the past.

Based on up to six years of clinical data, Sanofi found that patients of this type could suffer more cases of severe disease upon a subsequent dengue infection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK